EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Simultaneous Quantification of Vedolizumab, Ustekinumab, and Infliximab in Human Serum by LC-MS/MS: Application to Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Yanbao Zhang, Na Wang, Weiyang Zheng, Ruichen Liu, Limei Li, Xianglong Zhao, Xin Zheng, Xiaohong Han

Drug Design, Development and Therapy · 2026

DOI: 10.2147/dddt.s632769 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Yanbao Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Research Center, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major D…. Hauptthemen laut MEDLINE: Drug Monitoring, Inflammatory Bowel Diseases, Infliximab, Ustekinumab. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug MonitoringInflammatory Bowel DiseasesInfliximabUstekinumabAntibodies, Monoclonal, HumanizedHumansTandem Mass SpectrometryLiquid Chromatography-Mass SpectrometryChromatography, Liquid

Stichwörter der Autor:innen

LC-MS/MSinflammatory bowel diseasemonoclonal antibodiesprotein G immunocapturetherapeutic drug monitoring

Substanzen

vedolizumabInfliximabUstekinumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Clinical Pharmacology Research Center, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, Peking Union Medical College Hospital, Chinese Academy of Med…
  • Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
  • Application Engineering Department, SCIEX Analytical Instrument Trading Co., LTD, Beijing, People's Republic of China.

Zitieren

APA

Zhang, Y., Wang, N., Zheng, W., Liu, R., Li, L., Zhao, X., Zheng, X., & Han, X. (2026). Simultaneous Quantification of Vedolizumab, Ustekinumab, and Infliximab in Human Serum by LC-MS/MS: Application to Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s632769

Vancouver

Zhang Y, Wang N, Zheng W, Liu R, Li L, Zhao X, et al. Simultaneous Quantification of Vedolizumab, Ustekinumab, and Infliximab in Human Serum by LC-MS/MS: Application to Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s632769

BibTeX
@article{Zhang2026,
  author = {Zhang, Yanbao and Wang, Na and Zheng, Weiyang and Liu, Ruichen and Li, Limei and Zhao, Xianglong and Zheng, Xin and Han, Xiaohong},
  title = {Simultaneous Quantification of Vedolizumab, Ustekinumab, and Infliximab in Human Serum by LC-MS/MS: Application to Therapeutic Drug Monitoring in Inflammatory Bowel Disease},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  doi = {10.2147/dddt.s632769}
}
Kostenlos starten →